Yaya Guo1, Fahui Yin, Chunlei Fan, Zhilu Wang. 1. The First Medical Clinical College of Lanzhou University Department of Cardiology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Abstract
BACKGROUND AND OBJECTIVES: Previous researches have reported the controversial results regarding the gender difference in clinical outcomes of patients with coronary artery disease after percutaneous coronary intervention. Hence, this systematic review and meta-analysis was designed to investigate whether gender difference existed in patients with coronary artery disease after percutaneous coronary intervention. METHODS: PubMed, Embase, and the Cochrane Library database were searched up to February 10, 2018. Studies comparing the gender-specific effect on clinical outcomes of patients with coronary artery disease after percutaneous coronary intervention were identified, to analyze mortality, major adverse cardiovascular events (MACE) and revascularization. Statistical software RevMan was utilized in this meta-analysis. RESULTS: A total of 49 studies, involving 1,032,828 patients (774,115 males and 258,713 females) reporting gender-specific outcomes, were included in this study. The in-hospital mortality, 30-day mortality, 1-year mortality, and at least 2-years mortality in male patients with coronary artery disease after percutaneous coronary intervention were significantly lower than those of females (odds ratio [OR] 0.58 95% confidence interval [CI] 0.52-0.63, P < .001; OR 0.64, 95% CI 0.61-0.66, P = .04; OR 0.67, 95% CI 0.60-0.75, P < .001 and OR 0.71, 95% CI 0.63-0.79, P = .005, respectively). The MACE was significantly decreased in male subjects after initial percutaneous coronary intervention compared with females in <1-year or at least 1-year (OR 0.67, 95% CI 0.56-0.80, P < .001 and OR 0.84, 95% CI 0.76-0.93, P < .001). The male patients after percutaneous coronary intervention harbored higher rate of revascularization compared with females for at least 1-year (OR 1.17, 95% CI 1.00-1.36, P < .001), while the rate of revascularization in male patients for < 1-year was lower than that of females (OR 0.93, 95% CI 0.69-1.26, P < .001). CONCLUSIONS: The systematic review and meta-analysis suggests that the prognosis of male patients with coronary artery disease after percutaneous coronary intervention is better than that of females, except for long-term revascularization.
BACKGROUND AND OBJECTIVES: Previous researches have reported the controversial results regarding the gender difference in clinical outcomes of patients with coronary artery disease after percutaneous coronary intervention. Hence, this systematic review and meta-analysis was designed to investigate whether gender difference existed in patients with coronary artery disease after percutaneous coronary intervention. METHODS: PubMed, Embase, and the Cochrane Library database were searched up to February 10, 2018. Studies comparing the gender-specific effect on clinical outcomes of patients with coronary artery disease after percutaneous coronary intervention were identified, to analyze mortality, major adverse cardiovascular events (MACE) and revascularization. Statistical software RevMan was utilized in this meta-analysis. RESULTS: A total of 49 studies, involving 1,032,828 patients (774,115 males and 258,713 females) reporting gender-specific outcomes, were included in this study. The in-hospital mortality, 30-day mortality, 1-year mortality, and at least 2-years mortality in male patients with coronary artery disease after percutaneous coronary intervention were significantly lower than those of females (odds ratio [OR] 0.58 95% confidence interval [CI] 0.52-0.63, P < .001; OR 0.64, 95% CI 0.61-0.66, P = .04; OR 0.67, 95% CI 0.60-0.75, P < .001 and OR 0.71, 95% CI 0.63-0.79, P = .005, respectively). The MACE was significantly decreased in male subjects after initial percutaneous coronary intervention compared with females in <1-year or at least 1-year (OR 0.67, 95% CI 0.56-0.80, P < .001 and OR 0.84, 95% CI 0.76-0.93, P < .001). The male patients after percutaneous coronary intervention harbored higher rate of revascularization compared with females for at least 1-year (OR 1.17, 95% CI 1.00-1.36, P < .001), while the rate of revascularization in male patients for < 1-year was lower than that of females (OR 0.93, 95% CI 0.69-1.26, P < .001). CONCLUSIONS: The systematic review and meta-analysis suggests that the prognosis of male patients with coronary artery disease after percutaneous coronary intervention is better than that of females, except for long-term revascularization.
Coronary artery disease is the most common cardiovascular disease caused by coronary stenosis, spasm or occlusion. It is estimated that up to 23.3 million people will die of cardiovascular disease by 2030.[ To improve patient's viability, percutaneous coronary intervention (PCI) is the most commonly applied approach of reperfusion in many countries. However, multiple researches have pointed out that there were some prognostic differences between different genders.[ Some studies have showed persistent gender difference in outcomes after adjusting multivariate factors,[ while other studies also demonstrated that gender was not an independent factor for patient's outcome.[ Although previous meta-analysis has demonstrated the effect of gender on response to PCI, which not involved major adverse cardiovascular events (MACE) and revascularization, and the follow-up period was also comparatively short.[ Therefore, this meta-analysis was designed to determine the gender difference in patients with coronary artery disease after PCI, and provide evidence for the development of the guideline.
Materials and methods
Date source and search strategy
PubMed, Embase, and the Cochrane Library database were searched up to February 10, 2018. The following keywords and medical subject headings were utilized according to the “PICO” strategy: “coronary artery disease”, “percutaneous coronary intervention” or “PCI”, “gender”, or “sex”. Meanwhile, to prevent missing the related articles, the bibliography of the articles included in this study was retrieved manually. All analyses were based on previous published some studies, thus no ethical approval and patient consent are required.
Study selection and quality assessment
Three reviewers (YYG, FHY, and CLF) preliminarily and independently screened the articles that were eligible for study based on the title and summary. In the case of disagreements, the issues were solved through tripartite negotiation when checking the selected articles. The filtered article satisfied the following criteria: Coronary artery disease, including acute coronary syndrome, acute myocardial infarction, ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infraction, non-ST segment elevation acute coronary syndrome, unstable angina, and stable coronary artery disease; patients undergoing PCI; gender, sex, female, and male; gender-related different outcomes, including short and long-term mortality, MACE, revascularization. In this meta-analysis, all original articles were endeavored to collect, without considering case reports, summaries of the meeting or relevant comments of the original study. The Cochrane collaboration's tool[ and Newcastle–Ottawa scale[ were utilized to assess the quality of randomized controlled trials and observational studies.
Outcome definition
The outcomes of this pooled analysis included 3 primary endpoints, that was, mortality, MACE, and revascularization. The mortality was assessed mainly from in-hospital mortality, 30-day mortality, 1-year mortality, and at least 2-years mortality. The MACE and revascularization were divided by the cutoff of 1 year, including <1-year and at least 1-year MACE, revascularization for <1 year and at least 1 year.
Statistical analysis
Statistical software RevMan (version 5.3, Cochrane Collaboration Network) was utilized for data analysis in this meta-analysis. For all the outcomes, dichotomous data were pooled as Mantel–Haenszel odds ratio (OR) with the corresponding 95% confidence interval (CI). Statistical heterogeneity was evaluated by Chi-square test, which was showed by I statistic. Fixed effects models were employed in the case of no evidence of heterogeneity (I≥50%), otherwise random effects model was used. Subgroup analysis was performed to figure out sources of heterogeneity in the case of large heterogeneity. Sensitivity analysis was performed to determine whether any single study was primarily responsible for the final results. All statistical tests were two-tailed, and a P value < 0.05 was considered as statistical significance.
Results
Search results
A total of 6636 articles were retrieved, of which 157 related articles were identified after screening the title and abstract. Studies with subjects <100, non-English literature and those failed to meet the inclusion criteria of the study were excluded by reading the full text. Final only 49 nonrandomized control studies are included, which 13 studies were from Asian countries, 25 studies from European countries, 11 studies from North American, and 2 studies from Australia. The duration of follow-up varied from hospital stay to 30-day, and lasting to 7 years. The NOS was utilized to evaluate all the enrolled studies in this pooled analysis. Of them the quality score was 7 and 8 in 16 and the remaining 33 studies on the 0 to 10 scoring system, respectively (see Table, Supplemental Content, which illustrates the specific scores for each study).
Baseline data characteristics
Age, a history of hypertension, hyperlipidemia or dyslipidemia, diabetes mellitus, and smoking are reviewed by carefully reading the full text and summarizing the baseline data of each study (Table 1). Meanwhile, the male patients with coronary artery disease after PCI were found to harbor lower incidence of hypertension (OR 0.58, 95% CI 0.47–0.71, P < .001), diabetes (OR 0.72, 95% CI 0.68–0.77, P < .001), hyperlipidemia or dyslipidemia (OR 0.98, 95% CI 0.94–1.02, P < .001), and cardiogenic shock (OR 0.78, 95% CI 0.65–0.92, P < .001) compared with females. Although the smoking rate of male subjects (OR 2.65, 95% CI 2.16–3.24, P < .001) was higher than that of females, but the symptom onset time, door-to-balloon time and reperfusion time for female patients with coronary artery disease after PCI were longer than those of males (Table 2). In addition, the age of male patients is younger compared with females (Table 1).
Table 1
Characteristics of included studies.
Table 2
The ischemia-reperfusion time between different genders were mentioned in this study.
Characteristics of included studies.The ischemia-reperfusion time between different genders were mentioned in this study.
The mortality
The 24 studies (n = 430,914)[ reported on PCI postoperative in-hospital mortality, which show that the in-hospital mortality of male patients was significantly lower than that of females (OR 0.58, 95% CI 0.52–0.63, P < .001, I = 66%) (Fig. 1). This gender differences also reflect in 30-day mortality [OR 0.64, 95% CI 0.61–0.66, P = .04, I = 40%; 19 studies (n = 523,304)],[ 1-year mortality [OR 0.67, 95% CI 0.60–0.75, P < .001, I = 73%; 20 studies (n = 590,590)][ and >2-years mortality [OR 0.71, 95% CI 0.63–0.79, P = .005, I = 57%; 14 studies (n = 43,096)][ (Figs. 2–4). Due to the low heterogeneity (I2 < 50%) of the 30-day follow-up, the fixed effects models were used, without subgroup analysis. Other follow-up results showed that the I2 value was >50%. Subgroup analysis was carried out according to different prognostic factors. However, the source of heterogeneity could not be accurately identified, thus the random effects model was used. Sensitivity analysis indicated that the results of each group were relatively stable and reliable.
Figure 1
Forest plot of in-hospital mortality in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.
Figure 2
Forest plot of 30-day mortality in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.
Figure 4
Forest plot of at least 2-years mortality in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.
Forest plot of in-hospital mortality in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.Forest plot of 30-day mortality in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.Forest plot of 1-year mortality in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.Forest plot of at least 2-years mortality in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.
MACE
Pooled analysis of 15 studies (n = 230,477) shows that the incidence of MACE was lower in male patients with coronary artery disease after PCI compared with females in follow-up period of < 1-year (OR 0.67, 95% CI 0.56–0.80, P < .001, I = 88%)[ (Fig. 5). The male patients also experienced lower rate of MACE than females when the follow-up period was extended to at least 1-year [OR 0.84, 95% CI 0.76–0.93, P < .001, I = 74%; 17 studies (n = 111,903)][ (Fig. 6). The results of both groups displayed that the I2 value was >50%, but the appropriate factors for the high heterogeneity after adopted the subgroup analysis cannot be identified. Therefore, the meta-analysis of MACE was performed by random effects model. Sensitivity analysis showed that no single study was responsible for the overall effect size, and the results were stable and credible.
Figure 5
Forest plot of <1-year MACE in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.
Figure 6
Forest plot of the least 1-year MACE in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.
Forest plot of <1-year MACE in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.Forest plot of the least 1-year MACE in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.
The revascularization
The pooled data show that the revascularization rate in male patients with coronary artery disease after PCI was lower than that of females during a follow-up period of <1-year [OR 0.93, 95% CI 0.69–1.26, P < .001, I = 64%; 9 studies (n = 39,375)][ (Fig. 7), which was on opposite to the outcomes between male and female patients for at least 1-year [OR 1.17, 95% CI 1.00–1.36, P < .001, I = 71%; 16 studies (n = 37,770)[ (Fig. 8). The result showed that the I2 values of both groups were >50%. Random effects model was utilized, because the heterogeneity cannot be explained according to subgroup analysis. Sensitivity analysis indicated that the result was stable and relatively robust.
Figure 7
Forest plot of <1-year revascularization rate in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.
Figure 8
Forest plot of the least 1-year revascularization rate in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.
Forest plot of <1-year revascularization rate in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.Forest plot of the least 1-year revascularization rate in male vs female patients with coronary artery disease after PCI. PCI = percutaneous coronary intervention.
Discussion
The main results of this meta-analysis are as follows: the mortality in male patients with coronary artery disease after PCI was lower than that of females; the male patients with coronary artery disease after PCI harbored a lower incidence of MACE, no matter whether the follow-up period was <1 year or at least 1 year; the male patients with coronary artery disease after PCI overwhelmed females in long-term revascularization.The mortality in male patients with coronary artery disease after PCI was lower than that of females in this study both in short-term and long-term follow-up, which was consistent with previous systematic reviews.[ Because female subjects had much more hypertension, diabetes, dyslipidemia this meta-analysis, especially longer times of reperfusion ischemia,[ the latter may be caused by chest pain symptoms, which had not been fully explained in female patients with coronary artery disease, leading to delay prehospital visits. Therefore, the high mortality in female patients with coronary artery disease after PCI had been largely attributed to more adverse cardiovascular risk profiles compared with males. This meta-analysis has confirmed that the female patients with coronary artery disease were older than males, which may also attribute to the high mortality of female patients, and consistent with National Cardiovascular Data Registry ACTION Registry of America.[ Meanwhile, in this study, it had also been verified that the female subjects were more prone to suffer from cardiogenic shock, which was considered as another important indicator for higher mortality in female patients with coronary artery disease after PCI. The same consequences were obtained by meta-analysis by Kano et al.[ In short, it is an indisputable fact that the mortality in female patients with coronary artery disease after PCI was high.Similar to the above results, the male patients with coronary artery disease after PCI also had a lower incidence of MACE for <1 year or at least 1-year in this meta-analysis, which is a supplement and summary to previous systematic reviews and observational studies.[ The reasons for the above differences should first be attributed to the fact that the mortality in female patients with coronary artery disease after PCI is higher than that of males. Moreover, possessing more adverse cardiovascular risk profile was also an important factor for high incidence of MACE in female patients with coronary artery disease, the baseline data of this study had witnessed this proposition. The study of Jakobsen et al[ also showed female patients with coronary artery disease were burdened with more complications and worse hemodynamic status compared with males. The gender difference of MACE was still largely attributed to the higher incidence of heart failure in female patients with STEMI in some cohort.[ In summary, the above pathological factors had led to the high incidence of MACE in female patients with coronary artery disease after PCI. It is noteworthy that females had a worse clinical outcome, which reminds physicians should pay more attention to female patients in clinical practice.This systematic review and meta-analysis also showed that male patients with coronary artery disease after PCI had the advantages of revascularization compared with females in the long-term follow-up, which was consistent with the parts of previous observational studies,[ and supplied the main outcome of previous systematic reviews.[ This may be associated with more smoking in males from the baseline data of this study. On the contrary, the low incidence of revascularization in female subjects also included lower follow-up rates, atypical symptoms, difficult identification of myocardial ischemia, unwillingness of receiving invasive examinations, as well as the prejudices of doctor that female subjects might harbor lower rate of coronary arteriography during follow-up.[ In addition, female subjects with coronary artery disease after PCI had higher mortality during short and long-term follow-up, which might reduce the chance of next revascularization. Moreover, a research had indicated that the application of drug-eluting stents could decrease probability of coronary artery revascularization in female patients with PCI.[ Furthermore, the coronary artery of male patient with coronary artery disease is prone to harbor complicated lesions, including left main disease, chronic total occlusion and diffuse lesion.[ Meanwhile, male subjects suffering from more platelet-rich thrombus, atherosclerotic plaque rupture as well as micro-embolization were also demonstrated in some studies.[ The above-described pathophysiological difference would result in elevated risks of revascularization in male subjects. However, the female had a high incidence of <1-year revascularization, which was an integral part to <1-year MACE. Overall, the incidence of revascularization in female patients with coronary artery disease after PCI was higher than that of males in short-term follow-up, which was opposite in long-term follow-up showed the opposite result.
Limitations
Firstly, the main limitations of this study were that all articles included in this study were nonrandomized control studies. Therefore, many subjective factors were inevitable during the follow-up. Secondly, of the 1,032,828 patients included in the meta-analysis, the female patients accounted for only 1/4 of the total sample size. Thus, unequal distribution of gender may lead to a bias. Thirdly, there are large discrepancy in sample size and follow-up spans among different studies, which may lead to heterogeneity. Because most studies had larger heterogeneity, the random effects model was adopted; the results may weaken the large sample information with better quality. Fourthly, due to the lack of patient-level data, subgroup analysis was not conducted according to the type of subjects, and the specific prognosis of patients with different types of coronary artery disease undergoing PCI could not be assessed. Final, the language included in the study was limited to English, and there was a lack of researches in South America and Africa countries. Therefore, language and regional bias may be unavoidable.
Conclusions
In conclusion, the prognosis of male patients with coronary artery disease after PCI is better than that of females, except for long-term revascularization.
Acknowledgments
We would like to thank Professor Jinhui Tian of Evidence Based Medicine Center of Lanzhou University for guidance in the systematic search and statistical support.
Authors: Dharam J Kumbhani; Mehdi H Shishehbor; Joshua M Willis; Saima Karim; Dhssraj Singh; Anthony A Bavry; Edwin Zishiri; Stephen G Ellis; Venu Menon Journal: Am J Cardiol Date: 2012-01-14 Impact factor: 2.778
Authors: Elizabeth A Jackson; Mauro Moscucci; Dean E Smith; David Share; Simon Dixon; Adam Greenbaum; Paul M Grossman; Hitinder S Gurm Journal: Am Heart J Date: 2011-01 Impact factor: 4.749
Authors: Stephanie M Meller; Alexandra J Lansky; Ricardo A Costa; Morgan Soffler; Costantino O Costantini; Bruce R Brodie; David A Cox; Thomas D Stuckey; Martin Fahy; Cindy L Grines; Gregg W Stone Journal: Am J Cardiol Date: 2013-07-02 Impact factor: 2.778
Authors: Manon G van der Meer; Hendrik M Nathoe; Yolanda van der Graaf; Pieter A Doevendans; Yolande Appelman Journal: Eur J Clin Invest Date: 2015-02 Impact factor: 4.686
Authors: Hanan Idris; John K French; Ibrahim M Shugman; Andrew P Hopkins; Craig P Juergens; Liza Thomas Journal: Heart Lung Circ Date: 2016-12-02 Impact factor: 2.975
Authors: Lakshmana K Pendyala; Rebecca Torguson; Joshua P Loh; Hironori Kitabata; Sa'ar Minha; Salem Badr; Danny Dvir; Israel M Barbash; Lowell F Satler; Augusto D Pichard; Ron Waksman Journal: Am J Cardiol Date: 2013-01-24 Impact factor: 2.778
Authors: Ralf Birkemeyer; Henrik Schneider; Andreas Rillig; Juliane Ebeling; Ibrahim Akin; Stefan Kische; Liliya Paranskaya; Werner Jung; Hueseyin Ince; Christoph A Nienaber Journal: BMC Cardiovasc Disord Date: 2014-06-02 Impact factor: 2.298
Authors: Irene Valaker; Bengt Fridlund; Tore Wentzel-Larsen; Jan Erik Nordrehaug; Svein Rotevatn; Maj-Britt Råholm; Tone M Norekvål Journal: BMC Health Serv Res Date: 2020-01-31 Impact factor: 2.655
Authors: Elizabeth A Ellins; Daniel E Harris; Arron Lacey; Ashley Akbari; Fatemeh Torabi; Dave Smith; Geraint Jenkins; Daniel Obaid; Alex Chase; Ann John; Michael B Gravenor; Julian P Halcox Journal: PLoS One Date: 2022-02-25 Impact factor: 3.240